In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia
***Poster 1 Pre-assessment***

Before you view the poster session, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit. 

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.
1.What are your credentials? (Required.)
2.What is your specialty?
3.How confident are you in the management of patients with ALL in your practice?
Very confident
Confident
Neutral
Little confidence
No confidence
4.Which of the following best describes how asparaginase erwinia chrysanthemi (recombinant)-rywn (ERW-rywn) asparaginase erwinia chrysanthemi (ERW) are similar?(Required.)
5.SP is a 10-year-old male who developed a grade 3 hypersensitivity reaction after his 3rd dose of pegaspargase on COG protocol AALL0232 for high-risk ALL. The pharmacy is unable to obtain ERW due to drug shortage. 

Which of the following is most appropriate for SP?
(Required.)
6.Which of the following was observed in serum asparaginase activity in the phase 2/3 clinical trial that led to FDA-approval of asparaginase erwinia chrysanthemi (recombinant)-rywn (ERW-rywn) in cohort 1a (25 mg/m2 IM on Monday, Wednesday, Friday)?(Required.)
7.Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity) 
Privacy & Cookie Notice